An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Stopped early · Phase 2

Conditions studied: Advanced Cancer

In brief

The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer

Key facts

Study ID

NCT02750514

Run by

Bristol-Myers Squibb

People needed

295

Starts

2016-05-09

Expected to finish

2020-01-29

Last updated by the study team

2021-03-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced Non Small Cell Lung Cancer (NSCLC)
• Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1
• Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment
• Must have at least 1 lesion with measurable disease

You may not qualify if…

• Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment
• Subjects who need daily oxygen therapy
• People with autoimmune disease
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• City of Hope National Medical Center — Duarte, California, United States
• University of Southern California (USC) — Los Angeles, California, United States
• Cedars-Sinai Medical Center — Los Angeles, California, United States
• University of Californa, Los Angeles (UCLA) — Los Angeles, California, United States
• Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
• University of California San Diego — San Diego, California, United States
• University of Colorado Denver — Aurora, Colorado, United States
• Yale Cancer Center — New Haven, Connecticut, United States
• University of Kansas Cancer Center — Westwood, Kansas, United States
• University of Maryland - Marlene and Stewart Greenebaum Cancer Center — Baltimore, Maryland, United States
• Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana Farber/Harvard Cancer Center — Boston, Massachusetts, United States
• University of Michigan Health System (UMHS) - University Hospital (University of Michigan Medical Ce — Ann Arbor, Michigan, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Washington University, The Center for Advanced Medicine — St Louis, Missouri, United States
• Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Univ of NC Shool of Medicine — Chapel Hill, North Carolina, United States
• The Ohio State University — Columbus, Ohio, United States
• Northwest Cancer Specialists — Portland, Oregon, United States
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.